New pill shows promise against tough cancers in early trial
NCT ID NCT06994806
First seen Mar 07, 2026 · Last updated May 11, 2026 · Updated 9 times
Summary
This early-stage study tests a new daily pill, KQB168, alone or with another drug (pembrolizumab) in adults with advanced solid tumors that have stopped responding to immunotherapy. The main goals are to find a safe dose and see if the drug can shrink tumors. About 84 participants will take the pill daily and have frequent clinic visits for monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mary Crowley Cancer Research Centers
RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic - Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic - Phoenix
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic - Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Austin
RECRUITINGAustin, Texas, 78758, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Huston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Cancer Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT MD Anderson Cancer Center - Houston
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center- New Haven
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.